Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Pipeline Review, H2 2018
Summary
Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Telomerase Reverse Transcriptase Pipeline Review, H2 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complexassociated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and antiapoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 2, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Male Health, Respiratory, Hematological Disorders and Women's Health which include indications Prostate Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Alzheimer's Disease, Breast Cancer, Glioblastoma Multiforme GBM, Hepatocellular Carcinoma, Lung Cancer, NonSmall Cell Lung Cancer, Solid Tumor, Gastric Cancer, Ovarian Cancer, Aplastic Anemia, Benign Prostatic Hyperplasia, Bile Duct Cancer Cholangiocarcinoma, Blood Cancer, Chronic Lymphocytic Leukemia CLL, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, HormoneSensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Lung Adenocarcinoma, Lymphoma, Male Infertility, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Transitional Urothelial Tract Cancer, Myelodysplastic Syndrome, NonHodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PostEssential Thrombocythemia Myelofibrosis PostET MF, PostPolycythemia Vera Myelofibrosis PPVMF, Pulmonary Fibrosis, Renal Cell Carcinoma, Sarcomas, SmallCell Lung Cancer, Squamous NonSmall Cell Lung Cancer and Women Infertility.
Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49
The report reviews Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics and enlists all their major and minor projects
The report assesses Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope